Athira pharma announces topline results from act-ad phase 2 proof of concept study of fosgonimeton in mild-to-moderate alzheimer's disease

Primary endpoint of change in biomarker erp p300 latency was not statistically significant for the full study population as combination of fosgonimeton and standard-of-care (acheis) given together showed potential diminished effect of fosgonimeton
ATHA Ratings Summary
ATHA Quant Ranking